You are here

Oncoimmune Inc

Company Information
Address
9430 Key West Ave Ste 113
Rockville, MD 20850-6345
United States


http://www.oncoimmune.com

Information

UEI: G8WAHQ82DVC4

# of Employees: 8


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy

    Amount: $400,000.00

    Summary A major paradigm in cancer immunotherapy is to use checkpoint inhibitors to break regulatory mechanisms that guard the host against autoimmune diseases. CTLA-4-targeting immunotherapy was the ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health
  2. Cindi Study: A Phase II Clinical Trial to Combine CD24Fc with Ipilimumab and Nivolumab to Decrease Immune Related Adverse Events (irAE)

    Amount: $396,664.00

    Summary Combination of Ipilimumab and Nivolumab has emerged as the most effective cancer immunotherapy, resulting in 70% of metastatic melanoma patients to achieve survival beyond three years. However ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health
  3. Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.

    Amount: $312,714.00

    Project Summary AbstractThe recent rapid expansion of genomic data greatly contributes to the understanding of disease development and progressionTo translate these genetic discoveries into clinical a ...

    STTRPhase I2019Department of Health and Human Services National Institutes of Health
  4. SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients

    Amount: $2,999,396.00

    Summary Although most COVID-19 patients exhibit mild to moderate clinical symptoms, a substantial portion require hospitalization with oxygen support. These patients are classified as having severe CO ...

    SBIRPhase II2019Department of Health and Human Services National Institutes of Health
  5. A randomized, placebo-controlled, single-blinded clinical trial to assess safety and efficacy of CD24Fc in controlling cardiovascular disease risks of HIV-infected patients

    Amount: $212,653.00

    Project Summary Abstract Infection with Human Immunodeficiency VirusHIVaffects an estimatedmillion worldwideIn the United Statesan estimatedmillion people are infectedAs the access to antiretroviral t ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  6. A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.

    Amount: $2,004,306.00

    Project Summary AbstractAcute graft versus host diseaseaGVHDis a principal contributor to transplant related mortalityTRMand develops in approximatelyof recipients receiving unrelated donor hematopoie ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  7. Targeting endogenous sialidases for treatment of endotoxic shock

    Amount: $395,408.00

    DESCRIPTION provided by applicant Despite the advance of antibiotics sepsis remains a major challenge to human health as both survival and incidence of severe sepsis have been largely unchanged in ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
  8. Targeting host response to DAMP for therapy of Rheumatoid Arthritis

    Amount: $150,153.00

    DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is among the most common autoimmune diseases. The current treatment for RA is mainly by targeting tumor-necrosis factor (TNF). Despite th ...

    SBIRPhase I2011Department of Health and Human Services National Institutes of Health
  9. Novel Therapeutics for Sepsis

    Amount: $155,180.00

    DESCRIPTION (provided by applicant): Sepsis is one of the top leading causes of deaths for Americans and it is responsible for approximately 200,000 deaths in US annually. Despite of the advance of an ...

    SBIRPhase I2011Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government